Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Oncopeptides in connection with its rights issue
Mandate

Vinge has advised Oncopeptides in connection with its rights issue

March 14, 2024

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with issue proceeds of approximately SEK 300 million before deduction of transaction costs.

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Vinge’s team consisted of Dain Hård Nevonen, William Kåge, Joel Magnusson, Annie Fällström and Maximilian Bengtsson.

Related

Vinge advises Impilo on the establishment of a continuation fund

 Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.
November 15, 2024

Vinge advises Österlens Kraft economic association in connection with the sale of all shares in Österlens Kraft Fjärrvärme AB to Adven Sverige AB

 Österlens Kraft Fjärrvärme AB produces, distributes and sells district heating to the company's customers in Simrishamn.
November 14, 2024

Vinge advises Abacus Bidco Oy (which is the parent company of Accountor Software recently acquired by KKR) in the acquisition of certain subsidiaries and assets of 24SevenOffice Group AB (“24SevenOffice”)  

 24SevenOffice is a listed company (First North Stockholm) that provides modular software for accounting, ERP and business services that automate processes using AI.
November 13, 2024